Arvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+Palbociclib
Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) Thursday announced positive 6-month follow up data from a Phase 1b study evaluating vepdegestrant in combination with Pfizer's breast cancer drug Palbociclib in heavily pre-treated breast cancer patients. The …